Article Sidebar

PDF (Tiếng Việt)
Published: 2022-03-01
Abstract Views: 321
Views PDF (Tiếng Việt): 339
DOI: https://doi.org/10.52852/tcncyh.v151i3.611
Issue
Vol. 151 No. 3 (2022)
Section
Các bài báo
How to Cite
Dương, P. T. T. ., & Hùng, H. S. . (2022). Development of ovarian hyperstimulation syndrome in patients with GnRH agonist trigger. Journal of Medical Research, 151(3), 89-97. https://doi.org/10.52852/tcncyh.v151i3.611

Development of ovarian hyperstimulation syndrome in patients with GnRH agonist trigger

Pham Thi Thuy Duong, Ho Sy Hung

Main Article Content

Abstract

 Antagonist protocol combined with GnRH agonist trigger for oocyte maturation is an effective method
to reduce the risk of ovarian hyperstimulation syndrome (OHSS) in in vitro fertilization. However, this
protocol does not completely eliminate OHSS. This study aimed to describe the progression of OHSS
in patients who used GnRH agonists at the National Center for Assisted Reproduction from August
2020 to April 2021. Ninety-two patients were stimulated by antagonist protocol, and oocyte maturation
triggered by GnRH agonist were monitored for clinical and subclinical symptoms of OHSS at day 2
and day 7 after oocyte retrieval. The adverse gastrointestinal, urological, and respiratory symptoms
significantly decreased from day 2 to day 7 after oocyte retrieval. The rate of mild OHSS patients at day
2 and day 7 after oocyte retrieval was 19,6% and 1,1%, respectively, with no case of severe OHSS. This
protocol yielded favorable results about the rate of retrieved oocytes and the rate of mature oocyte.

Article Details

Keywords

ovarian hyperstimulation syndrome, GnRH agonist trigger, IVF

References

1. Toftager M, Bogstad J, Bryndorf T, et al. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles. Human Reproduction. 2016;31(6):1253 -1264. doi: 10.1093/humrep/dew051.
2. Borges E, Braga DPAF, Setti AS, Vingris LS, Figueira RCS, Iaconelli A. Strategies for the management of OHSS: Results from freezing-all cycles. JBRA Assist Reprod. 2016;20(1):8-12. doi: 10.5935/1518-0557.20160003.
3. Vuong TNL, Ho MT, Ha TD, Phung HT, Huynh GB, Humaidan P. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study. Fertility and Sterility. 2016;105(2):356-363. doi: 10.1016/j.fertnstert.2015.10.014.
4. La Thị Phương Thảo. So Sánh hiệu quả phòng ngừa hội chứng quá kích buồng trứng và chất lượng noãn của phác đồ gây trưởng thành noãn bằng GnRH Agonist và hCG. Luận văn Thạc sĩ Y học. Trường Đại học Y Hà Nội. 2016.
5. Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv. 1989;44(6):430-440. doi: 10.1097/000062 54-198906000-00004.
6. Herr K, Coyne PJ, McCaffery M, Manworren R, Merkel S. Pain Assessment in the Patient Unable to Self-Report: Position Statement with Clinical Practice Recommendations. Pain Management Nursing. 2011;12(4):230-250. doi: 10.1016/j.pmn.2011.10.002.
7. Mathur RS, Akande AV, Keay SD, Hunt LP, Jenkins JM. Distinction between early and late ovarian hyperstimulation syndrome. Fertility and Sterility. 2000;73(5):901-907. doi: 10.1016/S0015-0282(00)00492-1.
8. Mathur R, Evbuomwan I, Jenkins J. Prevention and management of ovarian hyperstimulation syndrome. Current Obstetrics & Gynaecology. 2002;12(2):111-116. doi: 10.10 54/cuog.2001.0243.
9. Wallach EE, Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertility and Sterility. 1992;58(2):249-261. doi: 10.1016/S0015-0282(16)55188-7.
10. Nguyễn Xuân Hợi, Nguyễn Viết Tiến. Các yếu tố tiên lượng sự đáp ứng của buồng trứng trong hỗ trợ sinh sản. Hội nghị Sản khoa Việt Pháp. 264-270.
11. Humaidan P, Quartarolo J, Papanikolaou EG. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertility and Sterility. 2010;94(2):389-400. doi: 10.1016/j.fertnstert.2010.03.028.
12. Ocal P, Sahmay S, Cetin M, Irez T, Guralp O, Cepni I. Serum anti-Müllerian hormone and antral follicle count as predictive markers of OHSS in ART cycles. J Assist Reprod Genet. 2011;28(12):1197-1203. doi: 10.1007/s10815-011-9627-4.
13. Krishna D, Dhoble S, Praneesh G, Rathore S, Upadhaya A, Rao K. Gonadotropin-releasing hormone agonist trigger is a better alternative than human chorionic gonadotropin in PCOS undergoing IVF cycles for an OHSS Free Clinic: A Randomized control trial. J Hum Reprod Sci. 2016;9(3):164-172. doi: 10.4103/0974-1208.192056.
14. Chu Thị Thu Hương. So sánh kết quả khởi động trưởng thành noãn bằng GnRH Agonist và hCG trên bệnh nhân được kích thích buồng trứng bằng phác đồ GnRH Antagonist tại Bệnh Viện Bưu Điện. Luận văn Thạc sĩ Y học. Trường Đại học Y Hà Nội. 2017.
15. Papanikolaou EG, Pozzobon C, Kolibianakis EM, et al. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertility and Sterility. 2006;85(1):112-120. doi: 10.1016/j.fertnstert.2005.07.1292.